Gemina Laboratories Ltd. (GLABF)
USD 0.44
(-2.91%)
USD 0.44
(-2.91%)
| Breakdown | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Operating Cash Flow | -3.24 Million | -4.5 Million | -3.87 Million | -319.09 Thousand |
| Net Income | -5.21 Million | -5.97 Million | -4.73 Million | -834.15 Thousand |
| Depreciation & Amortization | 93.36 Thousand | 50.28 Thousand | 43.83 Thousand | 12.09 Thousand |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | 565.01 Thousand | 392.95 Thousand | 702.32 Thousand | - |
| Change in working capital | 1.26 Million | 1.01 Million | 112.92 Thousand | 139.61 Thousand |
| Other non-cash items | 455.22 Thousand | 10.34 Thousand | 4105.00 | 391.47 Thousand |
| Investing Cash Flow | -41.35 Thousand | -505.06 Thousand | 8197.00 | 13.91 Thousand |
| Investments in PPE | -41.35 Thousand | -79.61 Thousand | -9803.00 | - |
| Acquisitions | - | - | - | 33.16 Thousand |
| Investment purchases | - | -429.2 Thousand | - | - |
| Sales/Maturities of investments | - | - | - | - |
| Other Investing Activities | - | 3750.00 | 18 Thousand | -19.25 Thousand |
| Financing Cash Flow | 3.2 Million | 3.94 Million | 4.13 Million | 2.72 Million |
| Debt repayment | -109.53 Thousand | -63.46 Thousand | -67.72 Thousand | - |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | 3.09 Million | 4.29 Million | 2.41 Million | 2.72 Million |
| Other Financing Activities | 200 Thousand | -292.93 Thousand | 1.78 Million | 1582.83 |
| Accounts receivables | 347.22 Thousand | -201.08 Thousand | -173.94 Thousand | -3937.00 |
| Accounts payables | - | - | - | - |
| Inventory | - | - | - | - |
| Other working capital | 916.8 Thousand | 1.21 Million | 286.86 Thousand | 143.55 Thousand |
| Cash at beginning of period | 83.09 Thousand | 1.15 Million | 881.94 Thousand | - |
| Cash at end of period | 990.00 | 83.09 Thousand | 1.15 Million | 2.41 Million |
| Capital Expenditure | -41.35 Thousand | -79.61 Thousand | -9803.00 | - |
| Effect of forex changes on cash | - | - | - | - |
| Net cash flow / Change in cash | -82.1 Thousand | -1.07 Million | 274.44 Thousand | 2.41 Million |
| Free Cash Flow | -3.28 Million | -4.58 Million | -3.88 Million | -319.09 Thousand |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -5.21 Million | -761.67 Thousand | -1.16 Million | -1.57 Million | -1.7 Million | -1.95 Million |
| Depreciation & Amortization | 93.36 Thousand | 26.6 Thousand | 27.41 Thousand | 20.64 Thousand | 18.7 Thousand | 14.28 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 565.01 Thousand | 97.67 Thousand | 105.21 Thousand | 183.34 Thousand | 178.78 Thousand | 180.68 Thousand |
| Change in working capital | 1.26 Million | 914.05 Thousand | 457.27 Thousand | 451.33 Thousand | -558.62 Thousand | 1.44 Million |
| Other non-cash items | 455.22 Thousand | -272.71 Thousand | 305.15 Thousand | 7358.00 | 6600.00 | -18.12 Thousand |
| Investing Cash Flow | -41.35 Thousand | 16.25 Thousand | -12.05 Thousand | -11.46 Thousand | -34.09 Thousand | -454.34 Thousand |
| Investments in PPE | -41.35 Thousand | 16.25 Thousand | -12.05 Thousand | -11.46 Thousand | -34.09 Thousand | -25.13 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | -429.2 Thousand |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | -429.21 |
| Financing Cash Flow | 3.2 Million | -26.42 Thousand | 172.96 Thousand | -20.2 Thousand | 3.07 Million | 282.33 Thousand |
| Debt repayment | -109.53 Thousand | -26.42 Thousand | -27.03 Thousand | -20.2 Thousand | -16.79 Thousand | -16.79 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 3.09 Million | - | - | - | 2.6 Million | 299.12 Thousand |
| Other Financing Activities | 200 Thousand | - | 200 Thousand | 1528.20 | 488.64 Thousand | -873.00 |
| Accounts receivables | 347.22 Thousand | 155.19 Thousand | 30.26 Thousand | 212.64 Thousand | -50.87 Thousand | 321.87 Thousand |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 916.8 Thousand | 758.86 Thousand | 427.01 Thousand | 238.68 Thousand | -507.75 Thousand | 1.12 Million |
| Cash at beginning of period | 83.09 Thousand | 2897.00 | 115.05 Thousand | 1.06 Million | 83.09 Thousand | 584.84 Thousand |
| Cash at end of period | 990.00 | 990.00 | 2897.00 | 115.05 Thousand | 1.06 Million | 83.09 Thousand |
| Capital Expenditure | -41.35 Thousand | 16.25 Thousand | -12.05 Thousand | -11.46 Thousand | -34.09 Thousand | -25.13 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -82.1 Thousand | -1907.00 | -112.15 Thousand | -947.12 Thousand | 979.08 Thousand | -501.74 Thousand |
| Free Cash Flow | -3.28 Million | 24.51 Thousand | -285.12 Thousand | -926.91 Thousand | -2.09 Million | -354.87 Thousand |
9939
NWI
ALIZY
X2M
0035
5857